Matthew A. Dean
Keine laufenden Positionen mehr
Karriereverlauf von Matthew A. Dean
Ehemalige bekannte Positionen von Matthew A. Dean
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Arriva Pharmaceuticals, Inc.
 Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Verwaltungsdirektor | - | 19.01.2011 |
USL Capital Corp.
 USL Capital Corp. Investment ManagersFinance Part of Ford Motor Co., USL Capital Corp. manages portfolios of commercial leases. The company is based in San Francisco, CA. | Corporate Officer/Principal | - | - |
| Cotelligent Group, Inc. | Corporate Officer/Principal | - | - |
| Silicon Energy Corp. | Verwaltungsdirektor | - | - |
| Finanzdirektor/CFO | - | - |
Ausbildung von Matthew A. Dean
| Claremont McKenna College | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Chief Administrative Officer | 2 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 2 |
| Consumer Services | 2 |
| Technology Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Arriva Pharmaceuticals, Inc.
Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Health Technology |
| Silicon Energy Corp. | Technology Services |
| Cotelligent Group, Inc. | |
USL Capital Corp.
USL Capital Corp. Investment ManagersFinance Part of Ford Motor Co., USL Capital Corp. manages portfolios of commercial leases. The company is based in San Francisco, CA. | Finance |
- Börse
- Insiders
- Matthew A. Dean
- Erfahrung
